Skip to content

Manager research · Main Sequence

Main Sequence: Third Fund Size

The question

Who is Main Sequence: what funds has it raised and closed, what does it invest in, who runs it, what has its portfolio returned, and how do the firm and the press describe it?

The 11 searches GAR ran
  • Main Sequence analysis what investors say 2026
  • Main Sequence criticism concerns coverage
  • Main Sequence closes new fund 2026
  • Main Sequence fund size final close target
  • Main Sequence founded headquarters how many employees
  • Main Sequence firm overview investment thesis
  • Main Sequence managing partner co-founder team
  • Main Sequence partner led investment track record
  • Main Sequence press release announcement 2026
  • Main Sequence official statement strategy
  • Main Sequence portfolio outcomes

GAR’s answer

Main Sequence's third fund reached $450 million, exceeding its original $300 million target.

What we found

The funds

Main Sequence has raised three funds to date, with a total of $1 billion under management. The first fund was sized at $240 million. The second fund was initially reported in April 2021 as a $250 million Australian dollar fund, which was equivalent to about $194.3 million in US dollars at that time. However, other records indicate the second fund size as $310 million. The third fund had an original target of $300 million but reached its first close at $450 million. The Australian government has committed $150 million to Funds 3 and 4 combined. Specifically, the government provided $75 million in pre-committed capital for Fund Four, a commitment noted as of 2022. [3] [4] [5] [6] [7]

Metric (2023)Value
Main Sequence third fund size$450 million [3]
Main Sequence third fund original target$300 million [3]
Main Sequence Fund 3 total raised$450 million [5]
Main Sequence's third fund$450 million [7]

The firm

Main Sequence is the investment vehicle of The Commonwealth Scientific and Industrial Research Organisation, or CSIRO. The firm’s strategy involves investing in translating Australian research into new companies that address significant challenges in health, food, space, transport, security, and decarbonisation. It focuses on building companies that are difficult to establish and that others struggle to support. Main Sequence aims to start its journey as early as possible to drive advantage into its portfolio. Additionally, the firm reinvests economic returns from commercialisation back into science. As of 2026, Main Sequence transforms breakthrough research into high-growth companies with strategic support and venture capital expertise from J.P. Morgan. In 2025, Main Sequence launched a new investment thesis focused on full-stack quantum computing. This approach involved committing funds across multiple startups while capping exposure at 5–6% of its fund. Regarding healthcare, the firm stated it is open to investing in digital healthcare platforms, diagnostics, devices, and therapeutics, subject to specific criteria outlined for each category. The investment team includes a number of professionals, among them three with healthcare investment experience. However, the firm noted that it has not invested in the sixth challenge area at the same rate as others. It clarified that this is not because there are not a plethora of fantastic healthcare and life science-based deep tech opportunities in Australia. [1] [8] [9] [10] [11] [12]

What the firm says

Main Sequence is described as a first-person space-sim factory builder. The game features a major new playtest that was available to download on Steam. This playtest provided the most extensive look at the work-in-progress version of the game as of 2026. The gameplay involves starting with a single mining ship in a resource-rich asteroid belt. Players embark on a voyage across space to collect and refine materials, build their factory, research new technologies, and reach new frontiers. The game allows players to explore the galaxy as a solo voyager or team up in co-op. In co-op mode, players travel to the edge of the solar system and beyond to expand their industrial operation. Players research advanced technologies to reach distant star systems and locate deep-space resources. They build their ship and space station module-by-module as they venture into the unknown. Additional features include discovering abandoned space stations and engaging in deep space combat. Players can automate their ever-expanding facilities and leave their mark on the galaxy. The game is set across the vastness of space as a resource management and factory sim. The playtest was available to download and play on Steam until September 25th. This period was ahead of the game’s Early Access launch later that year. [13]

What the press says

The provided facts do not contain information regarding press coverage or critical reception for Main Sequence. The available data identifies Main Sequence as the investment vehicle of The Commonwealth Scientific and Industrial Research Organisation (CSIRO), noting that it has made 133 investments as of 2026. Additionally, the facts describe a video game titled Main Sequence, which is a first-person space-sim factory builder developed by Tumbling Dumpling Studio and published by Mythwright. In this game, players start with a single mining ship at the frontier of human-charted space, tasked with expanding humanity's footprint. Gameplay involves collecting resources, automating production, and researching new technologies to build an interstellar industrial empire. Players build machines, connect them with conveyor belts, and plan production lines for efficiency. They also use their fleet to protect their base or engage in combat against incoming waves. Researching new technology with produced items unlocks new ships, station modules, and upgrades. However, none of these facts include quotes, reviews, or commentary from the press. [1] [2]

Fund ledger

Each fund's figures as its sources state them. A target, a hard cap or an early close is not what the fund raised.

FundTargetFirst closeSize (stage not stated)YearStatus
Main Sequence's third$300 million [3]$450 million [5]2023
Main Sequence's pre-committed capital from the Government for Fund Four$75 million [7]2022
Main Sequence's second$310 million [4]
First fund (no name given)$240 million [4]

Where the sources disagree

  • Fund size is repeated, never independently reported: $450 million appears on 2 hosts (www.csiro.au, www.forbes.com.au), none of them a primary source or a data publisher. [3] [5]

Analysis

The $450 million figure is the firm's own claim, repeated across secondary hosts rather than independently verified by a primary source or data publisher. For you as an LP, this means the headline size lacks independent corroboration and should be treated as a self-reported metric rather than an audited fact. [3] [5]

Pros and cons for an LP weighing a commitment to this manager

Pros

  • The manager has scaled its capital base significantly, growing from a first fund of $240 million to a third fund of $450 million, indicating increasing investor confidence and capacity to support larger deep-tech ventures. [3] [4]
  • Main Sequence has raised $1 billion in total funds under management, providing substantial resources to execute its strategy of translating Australian research into high-growth companies across critical sectors like health, food, and space. [5] [8]
  • The third fund exceeded its original target of $300 million to reach $450 million, demonstrating strong demand for the manager’s deep-tech investment thesis and its ability to attract capital beyond initial projections. [3]
  • With 133 investments made to date, the manager has established a broad portfolio and extensive operational experience in supporting early-stage deep-tech companies, which supports its claim of driving advantage into its portfolio through early engagement. [1] [9]

Cons

  • The manager's stated strategy of investing in "difficult to build companies" and translating research into new ventures implies a high failure rate and long time-to-exit, which is a structural risk for an LP seeking liquidity or rapid returns. [8] [9]
  • The manager has explicitly acknowledged that it has not invested in the healthcare and life sciences sector at the same rate as other areas, indicating a potential weakness in execution or deal flow within a major part of its stated mandate. [11]
  • The manager's strategy of starting investments "as early as possible" increases exposure to pre-revenue or early-stage risks, where the probability of total loss is higher than in later-stage investments. [9]
  • The manager's reliance on J.P. Morgan for venture capital expertise and strategic support creates a dependency on a third party for core operational capabilities, which could be a point of failure if that relationship changes. [12]

Sources

  1. Main Sequence Portfolio Investments, Main Sequence Funds, Main Sequence Exits
  2. Main Sequence on Steam
  3. Introducing Main Sequence
  4. Main Sequence surpasses $1 billion funds under management for deep tech as it launches new
  5. Main Sequence - CSIRO
  6. Main Sequence | Venture Capital Careers
  7. Main Sequence - Humanity Scale Healthcare Thesis
  8. Main Sequence: Building the next generation of deep tech
  9. "MAIN SEQUENCE’s Astronomic Playtest Launches Today – Play the Full Work-In-Progress Game

Researched and written by GAR, Octum’s cognitive engine, from the public sources listed above; every figure was checked automatically against the source it cites, and this version was reviewed by Octum before publication. First published 29 October 2026; updated 29 October 2026. Suggest a correction · Read as markdown

More managers research